Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non - Small-cell lung cancer cells in vitro and in vivo

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 1, 2015, Pages 91-99

  Du, Shisuo ^a   Bouquet, Sophie ^a   Lo, Chen Hao ^a   Pellicciotta, Ilenia ^a   Bolourchi, Shiva ^a   Parry, Renate ^b   Barcellos Hoff, Mary Helen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VARIAN MEDICAL SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOLOGICAL ORGANS; CELL CULTURE; CELLS; CYTOLOGY; DAMAGE DETECTION; DISEASES; DNA; GROWTH (MATERIALS); MAMMALS; MONOCLONAL ANTIBODIES; PHOSPHORYLATION; RADIATION; RADIOTHERAPY; TUMORS;

ATAXIA-TELANGIECTASIA MUTATED; NEUTRALIZING ANTIBODIES; NON SMALL CELL LUNG CANCER; NON-SMALL CELL LUNG CARCINOMATA; PROTEIN PHOSPHORYLATION; SMALL MOLECULE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTORS;

CELL SIGNALING;

ATM PROTEIN; HISTONE H2AX; NEUTRALIZING ANTIBODY; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; AMINO ACID; H2AFX PROTEIN, HUMAN; HISTONE; LY366457; MONOCLONAL ANTIBODY; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; XANTHENE DERIVATIVE;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; ADJUVANT CHEMOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; RADIATION DOSE; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COMET ASSAY; DNA DAMAGE; HISTONES; HUMANS; IN VITRO TECHNIQUES; LUNG NEOPLASMS; MICE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53; XANTHENES;

EID: 84923041358     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.09.026     Document Type: Article

References (29)

1. Kruse JJ, Floot BG, te Poele JA, et al. Radiation-induced activation of TGF-beta signaling pathways in relation to vascular damage in mouse kidneys. Radiat Res 2009;171:188-197.
2. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Cancer Rev 2011;11:239-253.
3. Hasegawa Y, Takanashi S, Kanehira Y, et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001;91:964-971.
4. Huang S, Hölzel M, Knijnenburg T, et al. Med12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 2012;151:937-950.
5. Du S, Barcellos-Hoff MH. Biologically augmenting radiation therapy by inhibiting TGF-β actions in carcinomas. Sem Radiat Oncol 2013;23:242-251.
6. Barcellos-Hoff MH, Cucinotta FA. New tricks for an old fox: Impact of TGFbeta on the DNA damage response and genomic stability. Sci Signal 2014;7:re5.
7. Kirshner J, Jobling MF, Pajares MJ, et al. Inhibition of TGFβ1 signaling attenuates ATM activity in response to genotoxic stress. Cancer Res 2006;66:10861-10868.
8. Zhang M, Herion TW, Timke C, et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia 2011; 13:537-549.
9. Mengxian Z, Kleber S, Röhrich M, et al. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71:7155-7167.
10. Hardee ME, Marciscano AE, MedinaRamirez CM, et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. Cancer Res 2012;72. Epub 2012 Jun 2012.
11. Bouquet SF, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti S, Barcellos-Hoff MH. Transforming growth factor β1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 2011;17:6754-6765.
12. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012;11:790-811.
13. Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography. Mutat Res 2012;751:158-246.
14. Bristow RG, Hill RP. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-192.
15. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3:1011-1022.
16. Akhurst RJ. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr Opin Investig Drugs 2006;7:513-521.
17. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-1078.
18. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
19. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
20. Villaruz LC, Socinski MA. Personalized therapy for non-small cell lung cancer: Which drug for which patient? Semin Thorac Cardiovasc Surg 2011;23:281-290.
21. Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: A novel treatment modality. Nat Rev Clin Oncol 2010;7:44-54.
22. Asai K, Shioyama Y, Nakamura K, et al. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: Risk factors and dose - volume relationship. Int J Radiat Oncol Biol Phys 2012;84:768-773.
23. Welcsh P, Lee M, Gonzalez-Hernandez R, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci U S A 2002;99:7560-7565.
24. Marquis S, Rajan J, Wynshaw-Boris A, et al. The developmental pattern of brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
25. Segawa Y, Kiura K, Takigawa N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010;28:3299-3306.
26. Topkan E, Parlak C, Topuk S, et al. Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIb non-small cell lung carcinoma: Retrospective analysis of 89 patients. Lung Cancer 2013;81:226-230.
27. Anscher MS, Kong F, Murase T, et al. Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF beta. Br J Radiat 1995;68:331-333.
28. Anscher MS, Thrasher B, Zgonjanin L, et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008;71:829-837.
29. Du S-S, Qiang M, Zeng Z-C, et al. Radiation-induced liver fibrosis is mitigated by gene therapy inhibiting transforming growth factor β signaling in the rat. Int J Radiat Oncol Biol Phys 2010;78:1513-1523.